Pharmicell (005690) — Capital Reinvestment Ratio
Latest as of September 2025:
0.07x
Pharmicell (005690) has a Capital Reinvestment Ratio of 0.07x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩8.78 Billion) in capital expenditures (₩622.48 Million). See 005690 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
₩8.78 Billion
KRW
Capital Expenditures
₩622.48 Million
KRW
Data as of
Sep 2025
Most recent filing
Pharmicell Capital Reinvestment Ratio (2016–2024)
This chart tracks Pharmicell's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Pharmicell (2016–2024)
Year-by-year Capital Reinvestment Ratio for Pharmicell from 2016 to 2024. For live market cap and broader valuation context, see Pharmicell market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.24x | ₩3.50 Billion | ₩4.34 Billion | ▲ +143.3% |
| 2023 | 0.51x | ₩11.81 Billion | ₩6.02 Billion | ▼ -78.7% |
| 2022 | 2.40x | ₩7.91 Billion | ₩18.96 Billion | ▲ +2795.5% |
| 2020 | 0.08x | ₩8.98 Billion | ₩742.73 Million | ▼ -94.0% |
| 2018 | 1.37x | ₩3.40 Billion | ₩4.68 Billion | ▼ -64.7% |
| 2016 | 3.89x | ₩988.97 Million | ₩3.85 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow